End Stage Renal Disease on DialysisTURBONCT05052151
Temperature and Bicarbonate: Hemodynamic Effects During Dialysis
A study testing Low dialysate temperature, High dialysate temperature and Low dialysate bicarbonate concentration in people with End Stage Renal Disease on Dialysis, run by University of Aarhus at 1 site in Denmark.
Trial summary
To elucidate the role of dialysate temperature and bicarbonate on hemodynamic parameters, plasma pH and electrolytes that potentially mediate this effect, the investigators wish to conduct a single-blinded, randomized, controlled, crossover study, specifically examining the effects of A fixed low temperature dialysate… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- End Stage Renal Disease on Dialysis
- What is being tested?
- Low dialysate temperature, High dialysate temperature and Low dialysate bicarbonate concentration
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteDenmark
- Study dates
- 25 Aug 2021to 3 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Regular dialysis (HD or HDF) therapy for >3 months
- Age >18 years
- Stable and functional arteriovenous (AV)-fistula
- Able to achieve a dialysis blood flow > 250 mL
- Able to stand up for a minimum of 10 min
- Able to undergo a 4 hour dialysis session without eating, drinking or sleeping
Show all 10Show fewer
- Proven cabable of cumulative ultrafiltration of 2% of end-dialytic weight (EDW)
- Able to give informed consent to participation in the study
- Hematocrit >30%
- BMI >18 and <35
Who cannot join
- Central venous catheter for HD or HDF
- Recirculation in AV-fistula
- Acute myocardial infarction within 3 months
- Atrial fibrillation
- Active malignant or infectious diseases
- Cerebrovascular incident within 3 months
Show all 9Show fewer
- Pregnancy
- Alcohol or drug abuse
- History of interruptions during HD or untimely termination of HD treatment
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Dialysis Clinic at Department of Renal Medicine, Aarhus University Hospital and affiliated dialysis clinics in Randers and Horsens
Aarhus, Region Midt, 8200
About this study
Official title: Hemodynamic Effects of Low vs. High Dialysate Temperature or Bicarbonate Concentration in Chronic Hemodialysis Patients
To elucidate the role of dialysate temperature and bicarbonate on hemodynamic parameters, plasma pH and electrolytes that potentially mediate this effect, the investigators wish to conduct a single-blinded, randomized, controlled, crossover study, specifically examining the effects of
- A fixed low temperature dialysate of 35°C compared to a fixed dialysate temperature of 37°C.
- A low dialysate bicarbonate concentration of 30 mmol/L compared to a high dialysate bicarbonate concentration of 38 mmol/L.
Read the detailed description
Background
Intradialytic hypotension (IDH) is a common complication of hemodialysis (HD) and is considered one of the most frequent complications with a prevalence between 10-12% depending on the definition of IDH (1). IDH has been associated with inefficient dialysis (2), vascular access thrombosis (3) and mortality (4,5).
Orthostatic hypotension (OH) is another common complication in HD with a prevalence around 42% in patients initiating HD treatment (6). OH is significantly associated with worse outcome in HD patients in terms of an increased two-year mortality (4) and increased risk of all-cause death (6).
Understanding the mechanisms underlying IDH and OH has the potential to optimize HD treatment, in order to minimize the occurrence of IDH and OH, potentially improving not only patient mortality and morbidity but also the everyday comfort of chronic HD patients when receiving dialysis treatment.
This study will investigate the hemodynamic effect of alterations in dialysate bicarbonate and dialysate temperature.
Dialysate temperature
Several clinical studies have examined the effect of low temperature dialysate (LTD) on IDH, but only few have examined the hemodynamic response in detail with intradialytic measurements of cardiac output (CO), central blood volume (CBV) and total peripheral resistance (TPR) (7-14). Generally, the studies confirm a blood pressure (BP) stabilizing effect of LTD, but diverse results are found on changes in CO, CBV and TPR. Some studies found greater increase in TPR during dialysis with LTD compared to a higher dialysate temperature (8,9,11,14). Other studies found that intradialytic CBV (7,12) and CO (12) improved considerably with LTD.
One previous study (14) examined OH in relation to use of LTD, but not with detailed intradialytic hemodynamic measurements. The study showed that both supine and upright mean arterial blood pressure (MAP) were significantly lower after dialysis with a dialysate temperature of 37°C compared to a dialysate temperature of 35°C. Furthermore, the increase in TPR was greater during dialysis with LTD.
Dialysate bicarbonate
Few studies have investigated the effect of dialysate bicarbonate (DB) concentration on intradialytic hemodynamics and results have been conflicting. Lower DB (from 32 to 26 mmol/L or a reduction of 6 mmol/L, respectively) was in two cross-over studies (15,16) shown to increase systolic BP (SBP) by approximately 5 mmHg, whereas a third study reported no significant effect on BP (17). One of these studies also found an increase in TPR with lower DB (16). IDH has been associated with lower DB in one of the previously mentioned cross-over studies (15), but this association was not found by Gabutti et al in 2005 (17) or in larger observational studies (17-19). Manipulation of DB inevitably affects plasma pH of the patient during dialysis. Thus, if pH decreases with DB-induced acidosis, hydrogen ions displace cations such as calcium from protein binding sites. DB-induced alkalosis on the other hand increases pH, which promotes increased protein binding, which decreases free cation levels. At the same time, intracellular sequestration of potassium at high pH levels has also been speculated to lower plasma potassium levels (20). Consequently, by changing DB a range of electrolytes including calcium are potentially affected which could impact neuromuscular function and thereby intradialytic hemodynamic parameters and the frequency of IDH and OH (17,21-26).
Hypotheses
Hemodialysis or hemodiafiltration (HdF) sessions with a decreased dialysate temperature (35°C vs. 37°C) or decreased DB concentration (30 mmol/L vs. 38 mmol/L) will have the following effects:
- An increase in SBP, MAP and orthostatic blood pressure (OBP).
- An increase in one or more of the following: Cardiac output (CO), total peripheral resistance (TPR), central blood volume (CBV), stroke volume (SV) and/or heart rate (HR).
- A decrease in the frequency of IDH and OH.
Study participants
Participants will be recruited from the maintenance HD and HdF population associated with the Department of Renal Medicine at Aarhus University Hospital in Denmark. These include the Dialysis Clinic at Aarhus University Hospital as the main hub and satellite dialysis clinics in Randers and Horsens.
Power and sample size
Measurements from 30 randomly selected HD patients in our clinic yielded SD = 23 mmHg for the difference between within-treatment changes in SBP (non-standardized conditions). Assuming a lower SD due to standardized BP-measurements and strict in- and exclusion criteria an SD = 12 mmHg was used as a reasonable estimate. Sample size calculation with Stata/IC 16.1 (StataCorp, 4905 Lakeway Dr, College Station, TX 77845, USA) using analysis for a one-sample mean test (t-test), assuming a minimal detectable difference in means (mean difference between the two within-treatment changes in SBP) = 10 mmHg; SD = 12 mmHg; two-sided significance level (alpha) = 0.05; power=0.80 resulted in 14 participants. However, to account for dropout of two participants, a sample size of 16 was chosen.
Dialysis machines, filters, and dialysate composition
Dialysis console Fresenius 5008F (Fresenius Medical Care, Bad Homburg, Germany) and HD or HdF filters regularly used for treatment of the patient will be used in all dialysis sessions.
The standard dialysate prescribed for each individual patient will be used in all dialysis sessions thereby maintaining similar composition regarding electrolytes such as sodium, potassium, calcium, magnesium and chloride. Bicarbonate concentration will only be adjusted in the sessions investigating low (30 mmol/L) and high (38 mmol/L) DB concentration, respectively. Dialysate will be prepared on-line by the dialysis machine. Blood flow rate and dialysate flow rate will be kept as usual and will remain equal in all sessions regardless of intervention. Ultrafiltration rate will be kept constant and equal in the two dialysis sessions. The same applies for the volume of substitution fluid in HdF.
Orthostatic hypotension (OH)
OH is defined as a reduction in SBP of at least 20 mmHg or in DBP of at least 10 mmHg within 3 minutes of standing (27).
Intradialytic hypotension (IDH)
IDH is defined as a decrease in SBP ≥20 mmHg or a decrease in MAP ≥10 mmHg associated with clinical events/symptoms (e.g. muscle cramps, abdominal discomfort, nausea or vomiting, dizziness or fainting, restlessness or anxiety, yawning or signing) and/or need for intradialytic interventions (Trendelenburg positioning, fluid administration, reduction in ultrafiltration rate, reduction of blood flow rate) or dialysis treatment cessation (28).
Intradialytic measurements
Cardiac output (CO) will be obtained by a previously validated ultrasound dilution technique using Hemodialysis Monitor HD03, Flow-QC tubing sets, and clip-on flow/dilution sensors from Transonic Systems Inc., Ithaca, NY, USA (29-32). The ultrasound sensors will be positioned on the arterial and venous Flow-QC tubing set using standard ultrasound gel to secure good contact. Access recirculation in the AV-fistula can invalidate CO-measurements. A built-in recirculation protocol will be used to check for access recirculation using injection of 10 mL isotonic saline into the venous blood line prior to the first CO-measurement. If recirculation is detected the dialysis needles will most likely be reinserted. CO will be measured in duplicate by injecting a bolus of 30 mL 37°C isotonic saline into the venous blood line within 5 seconds. If results deviate more than 15% a third measurement will be done. The mean of the two closest recordings will serve as the result. With the Transonic device intradialytic hemodynamic parameters are obtained at 10, 70, 130, 190, and 230 minutes. Patients will be lying in a supine position with the head elevated 20 degrees. Before each CO measurement HR and BP will be measured. MAP, TPR, and SV are derived by the following equations:
MAP = diastolic BP + 1/3 x (systolic BP - diastolic BP)
CO = SV x HR = MAP/TPR
CBV is defined as the volume of blood in the heart, lungs and great vessels and is estimated with the Transonic device based on the CO measurement.
Blood samples and handling of biological material
Following the same time pattern as the Transonic measurements an arterial blood gas will be drawn from the arterial cannula.
Eleven blood samples will be taken from the arterial blood line via the AV-cannula used for dialysis treatment. Four of the samples will be regular blood samples of 3-4 mL, whereas 7 of the samples will be arterial blood gases of 1 mL. Thus, per session 22 mL blood per participant is collected which adds up to a total of 88 mL for the entire study period. The purpose of this is to determine several essential parameters:
- Electrolytes such as calcium, magnesium, and potassium
- Acid-base status: pH, standard bicarbonate, standard base excess
- Hemoglobin, hematocrit
- Urea for the determination of Kt/V and URR.
- White cell count and C-reactive protein in the first blood sample in order to confirm the absence of infection
All blood samples will be transferred to the laboratory according to standard routine and analyzed according to current clinical standards at Department of Clinical Biochemistry, Aarhus University Hospital or local Department of Clinical Biochemistry normally servicing our satellite dialysis clinics in Randers and Horsens. Blood gas tests are analyzed using ABL blood gas analyzer (Radiometer, Radiometer Medical ApS, Brønshøj Denmark). All blood samples will be destroyed after analysis.
No samples will be stored in a biobank.
- Conditions
- End Stage Renal Disease on Dialysis
- Being tested
- Low dialysate temperature, High dialysate temperature, Low dialysate bicarbonate concentration, High dialysate bicarbonate concentration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low dialysate temperatureOther
35°C
High dialysate temperatureOther
37°C
Low dialysate bicarbonate concentrationOther
30 mmol/L
High dialysate bicarbonate concentrationOther
38 mmol/L
| Study group | Role | What they receive |
|---|---|---|
| Low temperature | Active comparator | Dialysate temperature Receives: Other: Low dialysate temperature |
| High temperature | Active comparator | Dialysate temperature Receives: Other: High dialysate temperature |
| Low bicarbonate | Active comparator | Dialysate bicarbonate concentration Receives: Other: Low dialysate bicarbonate concentration |
| High bicarbonate | Active comparator | Dialysate bicarbonate concentration Receives: Other: High dialysate bicarbonate concentration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood pressure (BP)
SBP (mmHg), Mean BP (mmHg) and Ortostatic BP (mmHg)
Measured: 4 weeks
Secondary outcomes (11)
Intradialytic cardiac output
CO (L/min)
Measured: 4 weeks
Intradialytic total peripheral resistance
TPR (mmHg/(L/min))
Measured: 4 weeks
Intradialytic stroke volume
SV (mL)
Measured: 4 weeks
Intradialytic heart rate
HR (beats/min)
Measured: 4 weeks
Intradialytic central blood volume
CBV (L)
Measured: 4 weeks
Intradialytic mean arterial blood pressure
MAP (mmHg)
Measured: 4 weeks
Plasma calcium
Calcium (mmol/L)
Measured: 4 weeks
Plasma potassium
Potassium (mmol/L)
Measured: 4 weeks
Plasma magnesium
Magnesium (mmol/L)
Measured: 4 weeks
Intradialytic hypotension (IDH)
IDH frequency (number of events)
Measured: 4 weeks
Ortostatic hypotension (OH)
OH frequency (number of events)
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2021
- Study start25 Aug 2021
- Primary completion20 Dec 2021
- Study completion3 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (36)Papers the sponsor has linked to this study.
- Other trials for End Stage Renal Disease on DialysisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- The study will be a single-blinded, randomized, controlled, crossover study with each participant being his or her own control. Participants will be blinded to the intervention and the order of the interventions will be random. Participants will be randomized using bloc randomization. We will create two blocs with 8 participants in each. The four dialysis sessions will be conducted on the same weekday each week, which results in a 1-week wash-out period with standard dialysis treatment between interventions.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Aarhus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Niels H Buus, Professor, Study chair, Department of Renal Medicine, Aarhus University HospitalJens D Jensen, MD, PhD, Study chair, Department of Renal Medicine, Aarhus University HospitalIna H Jørgensen, Student, Principal investigator, Department of Renal Medicine, Aarhus University HospitalJonas SK Jensen, Student, Principal investigator, Department of Renal Medicine, Aarhus University HospitalChristian D Peters, MD, PhD, Principal investigator, Department of Renal Medicine, Aarhus University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05052151
- Sponsor's protocol ID
- 23-06-21
- Acronym
- TURBO
- Status last verified
- Aug 2021
- First submitted
- 26 Aug 2021
- Last updated
- 18 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kuipers J, Verboom LM, Ipema KJR, Paans W, Krijnen WP, Gaillard CAJM, Westerhuis R, Franssen CFM. The Prevalence of Intradialytic Hypotension in Patients on Conventional Hemodialysis: A Systematic Review with Meta-Analysis. Am J Nephrol. 2019;49(6):497-506. doi: 10.1159/000500877. Epub 2019 May 24.
PubMed 31129661Ronco C, Brendolan A, Milan M, Rodeghiero MP, Zanella M, La Greca G. Impact of biofeedback-induced cardiovascular stability on hemodialysis tolerance and efficiency. Kidney Int. 2000 Aug;58(2):800-8. doi: 10.1046/j.1523-1755.2000.00229.x.
PubMed 10916105Chang TI, Paik J, Greene T, Desai M, Bech F, Cheung AK, Chertow GM. Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol. 2011 Aug;22(8):1526-33. doi: 10.1681/ASN.2010101119.
PubMed 21803971Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004 Sep;66(3):1212-20. doi: 10.1111/j.1523-1755.2004.00812.x.
PubMed 15327420Tisler A, Akocsi K, Borbas B, Fazakas L, Ferenczi S, Gorogh S, Kulcsar I, Nagy L, Samik J, Szegedi J, Toth E, Wagner G, Kiss I. The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. Nephrol Dial Transplant. 2003 Dec;18(12):2601-5. doi: 10.1093/ndt/gfg450.
PubMed 14605284Sasaki O, Nakahama H, Nakamura S, Yoshihara F, Inenaga T, Yoshii M, Kohno S, Kawano Y. Orthostatic hypotension at the introductory phase of haemodialysis predicts all-cause mortality. Nephrol Dial Transplant. 2005 Feb;20(2):377-81. doi: 10.1093/ndt/gfh614. Epub 2004 Dec 23.
PubMed 15618243Beerenhout C, Dejagere T, van der Sande FM, Bekers O, Leunissen KM, Kooman JP. Haemodynamics and electrolyte balance: a comparison between on-line pre-dilution haemofiltration and haemodialysis. Nephrol Dial Transplant. 2004 Sep;19(9):2354-9. doi: 10.1093/ndt/gfh315. Epub 2004 Jul 20.
PubMed 15266029Yu AW, Ing TS, Zabaneh RI, Daugirdas JT. Effect of dialysate temperature on central hemodynamics and urea kinetics. Kidney Int. 1995 Jul;48(1):237-43. doi: 10.1038/ki.1995.289.
PubMed 7564084van der Sande FM, Wystrychowski G, Kooman JP, Rosales L, Raimann J, Kotanko P, Carter M, Chan CT, Leunissen KM, Levin NW. Control of core temperature and blood pressure stability during hemodialysis. Clin J Am Soc Nephrol. 2009 Jan;4(1):93-8. doi: 10.2215/CJN.01800408. Epub 2008 Oct 8.
PubMed 18842948Selby NM, Burton JO, Chesterton LJ, McIntyre CW. Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol. 2006 Nov;1(6):1216-25. doi: 10.2215/CJN.02010606. Epub 2006 Oct 11.
PubMed 17699351Kaufman AM, Morris AT, Lavarias VA, Wang Y, Leung JF, Glabman MB, Yusuf SA, Levoci AL, Polaschegg HD, Levin NW. Effects of controlled blood cooling on hemodynamic stability and urea kinetics during high-efficiency hemodialysis. J Am Soc Nephrol. 1998 May;9(5):877-83. doi: 10.1681/ASN.V95877.
PubMed 9596086Hoeben H, Abu-Alfa AK, Mahnensmith R, Perazella MA. Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. Am J Kidney Dis. 2002 Jan;39(1):102-7. doi: 10.1053/ajkd.2002.29887.
PubMed 11774108Chesterton LJ, Selby NM, Burton JO, McIntyre CW. Cool dialysate reduces asymptomatic intradialytic hypotension and increases baroreflex variability. Hemodial Int. 2009 Apr;13(2):189-96. doi: 10.1111/j.1542-4758.2009.00355.x.
PubMed 19432693Jost CM, Agarwal R, Khair-el-Din T, Grayburn PA, Victor RG, Henrich WL. Effects of cooler temperature dialysate on hemodynamic stability in "problem" dialysis patients. Kidney Int. 1993 Sep;44(3):606-12. doi: 10.1038/ki.1993.287.
PubMed 8231034Gabutti L, Ferrari N, Giudici G, Mombelli G, Marone C. Unexpected haemodynamic instability associated with standard bicarbonate haemodialysis. Nephrol Dial Transplant. 2003 Nov;18(11):2369-76. doi: 10.1093/ndt/gfg383.
PubMed 14551368
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hemodynamic Effects of Low vs. High Dialysate Temperature or Bicarbonate Concentration in Chronic Hemodialysis Patients
- ClinicalTrials.gov ID
- NCT05052151
- Acronym / sponsor ID
- TURBO / 23-06-21
- Conditions
- End Stage Renal Disease on Dialysis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- University of AarhusUniversity, hospital or other
- Study start
- 25 Aug 2021 (actual)
- Primary completion
- 20 Dec 2021 (actual)
- Study completion
- 3 Jan 2022 (actual)
- First posted
- 22 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To elucidate the role of dialysate temperature and bicarbonate on hemodynamic parameters, plasma pH and electrolytes that potentially mediate this effect, the investigators wish to conduct a single-blinded, randomized, controlled, crossover study, specifically examining the effects of
- A fixed low temperature dialysate of 35°C compared to a fixed dialysate temperature of 37°C.
- A low dialysate bicarbonate concentration of 30 mmol/L compared to a high dialysate bicarbonate concentration of 38 mmol/L.
Detailed description
Background
Intradialytic hypotension (IDH) is a common complication of hemodialysis (HD) and is considered one of the most frequent complications with a prevalence between 10-12% depending on the definition of IDH (1). IDH has been associated with inefficient dialysis (2), vascular access thrombosis (3) and mortality (4,5).
Orthostatic hypotension (OH) is another common complication in HD with a prevalence around 42% in patients initiating HD treatment (6). OH is significantly associated with worse outcome in HD patients in terms of an increased two-year mortality (4) and increased risk of all-cause death (6).
Understanding the mechanisms underlying IDH and OH has the potential to optimize HD treatment, in order to minimize the occurrence of IDH and OH, potentially improving not only patient mortality and morbidity but also the everyday comfort of chronic HD patients when receiving dialysis treatment.
This study will investigate the hemodynamic effect of alterations in dialysate bicarbonate and dialysate temperature.
Dialysate temperature
Several clinical studies have examined the effect of low temperature dialysate (LTD) on IDH, but only few have examined the hemodynamic response in detail with intradialytic measurements of cardiac output (CO), central blood volume (CBV) and total peripheral resistance (TPR) (7-14). Generally, the studies confirm a blood pressure (BP) stabilizing effect of LTD, but diverse results are found on changes in CO, CBV and TPR. Some studies found greater increase in TPR during dialysis with LTD compared to a higher dialysate temperature (8,9,11,14). Other studies found that intradialytic CBV (7,12) and CO (12) improved considerably with LTD.
One previous study (14) examined OH in relation to use of LTD, but not with detailed intradialytic hemodynamic measurements. The study showed that both supine and upright mean arterial blood pressure (MAP) were significantly lower after dialysis with a dialysate temperature of 37°C compared to a dialysate temperature of 35°C. Furthermore, the increase in TPR was greater during dialysis with LTD.
Dialysate bicarbonate
Few studies have investigated the effect of dialysate bicarbonate (DB) concentration on intradialytic hemodynamics and results have been conflicting. Lower DB (from 32 to 26 mmol/L or a reduction of 6 mmol/L, respectively) was in two cross-over studies (15,16) shown to increase systolic BP (SBP) by approximately 5 mmHg, whereas a third study reported no significant effect on BP (17). One of these studies also found an increase in TPR with lower DB (16). IDH has been associated with lower DB in one of the previously mentioned cross-over studies (15), but this association was not found by Gabutti et al in 2005 (17) or in larger observational studies (17-19). Manipulation of DB inevitably affects plasma pH of the patient during dialysis. Thus, if pH decreases with DB-induced acidosis, hydrogen ions displace cations such as calcium from protein binding sites. DB-induced alkalosis on the other hand increases pH, which promotes increased protein binding, which decreases free cation levels. At the same time, intracellular sequestration of potassium at high pH levels has also been speculated to lower plasma potassium levels (20). Consequently, by changing DB a range of electrolytes including calcium are potentially affected which could impact neuromuscular function and thereby intradialytic hemodynamic parameters and the frequency of IDH and OH (17,21-26).
Hypotheses
Hemodialysis or hemodiafiltration (HdF) sessions with a decreased dialysate temperature (35°C vs. 37°C) or decreased DB concentration (30 mmol/L vs. 38 mmol/L) will have the following effects:
- An increase in SBP, MAP and orthostatic blood pressure (OBP).
- An increase in one or more of the following: Cardiac output (CO), total peripheral resistance (TPR), central blood volume (CBV), stroke volume (SV) and/or heart rate (HR).
- A decrease in the frequency of IDH and OH.
Study participants
Participants will be recruited from the maintenance HD and HdF population associated with the Department of Renal Medicine at Aarhus University Hospital in Denmark. These include the Dialysis Clinic at Aarhus University Hospital as the main hub and satellite dialysis clinics in Randers and Horsens.
Power and sample size
Measurements from 30 randomly selected HD patients in our clinic yielded SD = 23 mmHg for the difference between within-treatment changes in SBP (non-standardized conditions). Assuming a lower SD due to standardized BP-measurements and strict in- and exclusion criteria an SD = 12 mmHg was used as a reasonable estimate. Sample size calculation with Stata/IC 16.1 (StataCorp, 4905 Lakeway Dr, College Station, TX 77845, USA) using analysis for a one-sample mean test (t-test), assuming a minimal detectable difference in means (mean difference between the two within-treatment changes in SBP) = 10 mmHg; SD = 12 mmHg; two-sided significance level (alpha) = 0.05; power=0.80 resulted in 14 participants. However, to account for dropout of two participants, a sample size of 16 was chosen.
Dialysis machines, filters, and dialysate composition
Dialysis console Fresenius 5008F (Fresenius Medical Care, Bad Homburg, Germany) and HD or HdF filters regularly used for treatment of the patient will be used in all dialysis sessions.
The standard dialysate prescribed for each individual patient will be used in all dialysis sessions thereby maintaining similar composition regarding electrolytes such as sodium, potassium, calcium, magnesium and chloride. Bicarbonate concentration will only be adjusted in the sessions investigating low (30 mmol/L) and high (38 mmol/L) DB concentration, respectively. Dialysate will be prepared on-line by the dialysis machine. Blood flow rate and dialysate flow rate will be kept as usual and will remain equal in all sessions regardless of intervention. Ultrafiltration rate will be kept constant and equal in the two dialysis sessions. The same applies for the volume of substitution fluid in HdF.
Orthostatic hypotension (OH)
OH is defined as a reduction in SBP of at least 20 mmHg or in DBP of at least 10 mmHg within 3 minutes of standing (27).
Intradialytic hypotension (IDH)
IDH is defined as a decrease in SBP ≥20 mmHg or a decrease in MAP ≥10 mmHg associated with clinical events/symptoms (e.g. muscle cramps, abdominal discomfort, nausea or vomiting, dizziness or fainting, restlessness or anxiety, yawning or signing) and/or need for intradialytic interventions (Trendelenburg positioning, fluid administration, reduction in ultrafiltration rate, reduction of blood flow rate) or dialysis treatment cessation (28).
Intradialytic measurements
Cardiac output (CO) will be obtained by a previously validated ultrasound dilution technique using Hemodialysis Monitor HD03, Flow-QC tubing sets, and clip-on flow/dilution sensors from Transonic Systems Inc., Ithaca, NY, USA (29-32). The ultrasound sensors will be positioned on the arterial and venous Flow-QC tubing set using standard ultrasound gel to secure good contact. Access recirculation in the AV-fistula can invalidate CO-measurements. A built-in recirculation protocol will be used to check for access recirculation using injection of 10 mL isotonic saline into the venous blood line prior to the first CO-measurement. If recirculation is detected the dialysis needles will most likely be reinserted. CO will be measured in duplicate by injecting a bolus of 30 mL 37°C isotonic saline into the venous blood line within 5 seconds. If results deviate more than 15% a third measurement will be done. The mean of the two closest recordings will serve as the result. With the Transonic device intradialytic hemodynamic parameters are obtained at 10, 70, 130, 190, and 230 minutes. Patients will be lying in a supine position with the head elevated 20 degrees. Before each CO measurement HR and BP will be measured. MAP, TPR, and SV are derived by the following equations:
MAP = diastolic BP + 1/3 x (systolic BP - diastolic BP)
CO = SV x HR = MAP/TPR
CBV is defined as the volume of blood in the heart, lungs and great vessels and is estimated with the Transonic device based on the CO measurement.
Blood samples and handling of biological material
Following the same time pattern as the Transonic measurements an arterial blood gas will be drawn from the arterial cannula.
Eleven blood samples will be taken from the arterial blood line via the AV-cannula used for dialysis treatment. Four of the samples will be regular blood samples of 3-4 mL, whereas 7 of the samples will be arterial blood gases of 1 mL. Thus, per session 22 mL blood per participant is collected which adds up to a total of 88 mL for the entire study period. The purpose of this is to determine several essential parameters:
- Electrolytes such as calcium, magnesium, and potassium
- Acid-base status: pH, standard bicarbonate, standard base excess
- Hemoglobin, hematocrit
- Urea for the determination of Kt/V and URR.
- White cell count and C-reactive protein in the first blood sample in order to confirm the absence of infection
All blood samples will be transferred to the laboratory according to standard routine and analyzed according to current clinical standards at Department of Clinical Biochemistry, Aarhus University Hospital or local Department of Clinical Biochemistry normally servicing our satellite dialysis clinics in Randers and Horsens. Blood gas tests are analyzed using ABL blood gas analyzer (Radiometer, Radiometer Medical ApS, Brønshøj Denmark). All blood samples will be destroyed after analysis.
No samples will be stored in a biobank.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 4
- Model description
- The study will be a single-blinded, randomized, controlled, crossover study with each participant being his or her own control. Participants will be blinded to the intervention and the order of the interventions will be random. Participants will be randomized using bloc randomization. We will create two blocs with 8 participants in each. The four dialysis sessions will be conducted on the same weekday each week, which results in a 1-week wash-out period with standard dialysis treatment between interventions.
| Arm | Type | Receives |
|---|---|---|
| Low temperature | Active comparator | Other: Low dialysate temperatureDialysate temperature |
| High temperature | Active comparator | Other: High dialysate temperatureDialysate temperature |
| Low bicarbonate | Active comparator | Other: Low dialysate bicarbonate concentrationDialysate bicarbonate concentration |
| High bicarbonate | Active comparator | Other: High dialysate bicarbonate concentrationDialysate bicarbonate concentration |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Regular dialysis (HD or HDF) therapy for >3 months
- Age >18 years
- Stable and functional arteriovenous (AV)-fistula
- Able to achieve a dialysis blood flow > 250 mL
- Able to stand up for a minimum of 10 min
Key exclusion criteria (9 listed)
- Central venous catheter for HD or HDF
- Recirculation in AV-fistula
- Acute myocardial infarction within 3 months
- Atrial fibrillation
- Active malignant or infectious diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low dialysate temperature35°C | Other | Low temperature |
| High dialysate temperature37°C | Other | High temperature |
| Low dialysate bicarbonate concentration30 mmol/L | Other | Low bicarbonate |
| High dialysate bicarbonate concentration38 mmol/L | Other | High bicarbonate |
Primary outcome
Blood pressure (BP)
Time frame: 4 weeks
SBP (mmHg), Mean BP (mmHg) and Ortostatic BP (mmHg)
11 secondary outcomes
Intradialytic cardiac output
Time frame: 4 weeks
Intradialytic total peripheral resistance
Time frame: 4 weeks
Intradialytic stroke volume
Time frame: 4 weeks
Intradialytic heart rate
Time frame: 4 weeks
Intradialytic central blood volume
Time frame: 4 weeks
Intradialytic mean arterial blood pressure
Time frame: 4 weeks
Plasma calcium
Time frame: 4 weeks
Plasma potassium
Time frame: 4 weeks
Plasma magnesium
Time frame: 4 weeks
Intradialytic hypotension (IDH)
Time frame: 4 weeks
Ortostatic hypotension (OH)
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2022.
- Background: PubMed 31129661Kuipers J, Verboom LM, Ipema KJR, Paans W, Krijnen WP, Gaillard CAJM, Westerhuis R, Franssen CFM. The Prevalence of Intradialytic Hypotension in Patients on Conventional Hemodialysis: A Systematic Review with Meta-Analysis. Am J Nephrol. 2019;49(6):497-506. doi: 10.1159/000500877. Epub 2019 May 24.
- Background: PubMed 10916105Ronco C, Brendolan A, Milan M, Rodeghiero MP, Zanella M, La Greca G. Impact of biofeedback-induced cardiovascular stability on hemodialysis tolerance and efficiency. Kidney Int. 2000 Aug;58(2):800-8. doi: 10.1046/j.1523-1755.2000.00229.x.
- Background: PubMed 21803971Chang TI, Paik J, Greene T, Desai M, Bech F, Cheung AK, Chertow GM. Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol. 2011 Aug;22(8):1526-33. doi: 10.1681/ASN.2010101119.
- Background: PubMed 15327420Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004 Sep;66(3):1212-20. doi: 10.1111/j.1523-1755.2004.00812.x.
- Background: PubMed 14605284Tisler A, Akocsi K, Borbas B, Fazakas L, Ferenczi S, Gorogh S, Kulcsar I, Nagy L, Samik J, Szegedi J, Toth E, Wagner G, Kiss I. The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. Nephrol Dial Transplant. 2003 Dec;18(12):2601-5. doi: 10.1093/ndt/gfg450.
- Background: PubMed 15618243Sasaki O, Nakahama H, Nakamura S, Yoshihara F, Inenaga T, Yoshii M, Kohno S, Kawano Y. Orthostatic hypotension at the introductory phase of haemodialysis predicts all-cause mortality. Nephrol Dial Transplant. 2005 Feb;20(2):377-81. doi: 10.1093/ndt/gfh614. Epub 2004 Dec 23.
- Background: PubMed 15266029Beerenhout C, Dejagere T, van der Sande FM, Bekers O, Leunissen KM, Kooman JP. Haemodynamics and electrolyte balance: a comparison between on-line pre-dilution haemofiltration and haemodialysis. Nephrol Dial Transplant. 2004 Sep;19(9):2354-9. doi: 10.1093/ndt/gfh315. Epub 2004 Jul 20.
- Background: PubMed 7564084Yu AW, Ing TS, Zabaneh RI, Daugirdas JT. Effect of dialysate temperature on central hemodynamics and urea kinetics. Kidney Int. 1995 Jul;48(1):237-43. doi: 10.1038/ki.1995.289.
- Background: PubMed 18842948van der Sande FM, Wystrychowski G, Kooman JP, Rosales L, Raimann J, Kotanko P, Carter M, Chan CT, Leunissen KM, Levin NW. Control of core temperature and blood pressure stability during hemodialysis. Clin J Am Soc Nephrol. 2009 Jan;4(1):93-8. doi: 10.2215/CJN.01800408. Epub 2008 Oct 8.
- Background: PubMed 17699351Selby NM, Burton JO, Chesterton LJ, McIntyre CW. Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol. 2006 Nov;1(6):1216-25. doi: 10.2215/CJN.02010606. Epub 2006 Oct 11.
- Background: PubMed 9596086Kaufman AM, Morris AT, Lavarias VA, Wang Y, Leung JF, Glabman MB, Yusuf SA, Levoci AL, Polaschegg HD, Levin NW. Effects of controlled blood cooling on hemodynamic stability and urea kinetics during high-efficiency hemodialysis. J Am Soc Nephrol. 1998 May;9(5):877-83. doi: 10.1681/ASN.V95877.
- Background: PubMed 11774108Hoeben H, Abu-Alfa AK, Mahnensmith R, Perazella MA. Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. Am J Kidney Dis. 2002 Jan;39(1):102-7. doi: 10.1053/ajkd.2002.29887.
- Individual participant dataSharing planned: No
Related trials for End Stage Renal Disease on Dialysis
RecruitingPhase 2
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication
Not yet recruiting
Acupuncture for Symptom Burden and Quality of Life in Patients With End-Stage Kidney Disease
End Stage Kidney Disease (ESKD)
RecruitingPhase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
End-Stage Kidney Disease, End-Stage Renal Disease
RecruitingPhase 1
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
Kidney Transplant, Kidney Failure
Recruiting
Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis
End Stage Renal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Niels H Buus, Professor study chair
Department of Renal Medicine, Aarhus University Hospital
Jens D Jensen, MD, PhD study chair
Department of Renal Medicine, Aarhus University Hospital
Ina H Jørgensen, Student principal investigator
Department of Renal Medicine, Aarhus University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low dialysate temperature, High dialysate temperature and Low dialysate bicarbonate concentration in people with End Stage Renal Disease on Dialysis, run by University of Aarhus at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood pressure (BP) (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05052151, which also lists 36 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2022.